A nanoparticle used in 3D printing is disclosed herein. In an example, the nanoparticle can comprise: at least one metal oxide, which absorbs infrared light in a range of from about 780 nm to about 2300 nm and is shown in formula (1):

M.sub.mM′O.sub.n  (1)

wherein M is an alkali metal, m is greater than 0 and less than 1, M′ is any metal, and n is greater than 0 and less than or equal to 4; and a bilayer-forming surfactant encapsulating at least a portion of the metal oxide, wherein the nanoparticle has a diameter of from about 0.1 nm to about 500 nm.

A nanoparticle used in 3D printing is disclosed herein. In an example, the nanoparticle can comprise: at least one metal oxide, which absorbs infrared light in a range of from about 780 nm to about 2300 nm and is shown in formula (1):

M.sub.mM′O.sub.n  (1)

wherein M is an alkali metal, m is greater than 0 and less than 1, M′ is any metal, and n is greater than 0 and less than or equal to 4; and a bilayer-forming surfactant encapsulating at least a portion of the metal oxide, wherein the nanoparticle has a diameter of from about 0.1 nm to about 500 nm.

An object is to provide a lipid particle that is not positively charged at a pH of the body fluid (typically in the neutral range), and that enables efficient onset of the effect of a medicinal substance encapsulated in the lipid particle; and to provide a lipid for forming the lipid particle. The object is achieved by the phospholipid represented by formula (1), and a lipid particle containing the phospholipid: ##STR00001##
wherein R.sup.1 and R.sup.2 are identical or different, and represent a chain hydrocarbon group, m represents 1 or 2, n represents 1 or 2, and p represents an integer of 1 to 4.

An object is to provide a lipid particle that is not positively charged at a pH of the body fluid (typically in the neutral range), and that enables efficient onset of the effect of a medicinal substance encapsulated in the lipid particle; and to provide a lipid for forming the lipid particle. The object is achieved by the phospholipid represented by formula (1), and a lipid particle containing the phospholipid: ##STR00001##
wherein R.sup.1 and R.sup.2 are identical or different, and represent a chain hydrocarbon group, m represents 1 or 2, n represents 1 or 2, and p represents an integer of 1 to 4.

Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein are methods of treating cancer in a subject and methods of targeting a drug to a tumor or cancer cell in a subject.

New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.

New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.

The present application relates to extracting a plurality of compounds from a traditional Chinese medicine, or synthesizing a compound capable of promoting nucleic acid delivery, and utilizing the extracted compound, or a plurality of combinations to promote absorption and entry of a nucleic acid such as sRNA into a target cell, and to facilitate the entry of a nucleic acid into a target site in a subject in need thereof.

The present application relates to extracting a plurality of compounds from a traditional Chinese medicine, or synthesizing a compound capable of promoting nucleic acid delivery, and utilizing the extracted compound, or a plurality of combinations to promote absorption and entry of a nucleic acid such as sRNA into a target cell, and to facilitate the entry of a nucleic acid into a target site in a subject in need thereof.

This invention provides a technique that is capable of suppressing variation in the amount of phospholipids obtained in each operation when a phospholipid concentrate is obtained by subjecting an ethanol extract concentrate of livestock or poultry tissue to a degumming step and collecting gum. More specifically, the invention provides a method for producing a phospholipid concentrate from livestock or poultry tissue, comprising step (A) of mixing an ethanol extract concentrate of livestock or poultry tissue with water, the water being in an amount of less than 7 parts by mass per 100 parts by mass of the concentrate, and step (B) of centrifuging the obtained liquid mixture at 2° C. or lower.